AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Viekira [legacy through FY20Q1] by Quarter
Viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M)
AbbVie Viekira [legacy through FY20Q1]: $4M in Q4 2019, down 90.7% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2019 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2020-02-21) ↗
Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Viekira (ombitasvir/paritaprevir/ritonavir) [legacy through FY20Q1] — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2019 | Dec 31, 2019 | 4 | -90.7% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2019 | Sep 30, 2019 | 3 | -87.0% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 4 | -90.2% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 25 | -64.8% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 43 | -62.6% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2018 | Sep 30, 2018 | 23 | -87.3% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 41 | – | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2018 | Mar 31, 2018 | 71 | – | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2017 | Dec 31, 2017 | 115 | – | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2017 | Sep 30, 2017 | 181 | – | Form 10-Q (filed 2018-11-07) ↗ |
Breakdown
What makes up viekira [legacy through FY20Q1]
Cite this data
StockData. (2026). AbbVie Viekira [legacy through FY20Q1] ($M), quarterly Q3 2017–Q4 2019 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/viekira-ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.